NCT05165459Unknown不适用
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers
Szeged University2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2021年11月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Reduction rate of the wound size
研究概览
简要总结
To evaluate the efficacy and safety of Cytori Celution System in Hungarian patients with chronic non-healing venous leg ulcers.
详细描述
This motive trial can help to establish routine application of this internationally widely used device at University of Szeged. The primary outcome is the reduction rate of the wound size. The treatment response will be calculated from wound size before and after treatment. Any adverse events related to the study device will be monitored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Males or females age ≥ 18
- •At least one venous chronic leg ulcer with the following condition 3.
- •Ulcer is present beyond 2 months 3.
- •Conservative treatment not leading to improvement 3.
- •Wound size between ≥5 and ≤100 cm2
- •Ability to safely undergo tissue harvest that is anticipated to yield >100mL of adipose tissue at a site that is free from infection and injury
- •Able and willing to work with the doctor, adhere to therapeutic prescriptions and appear on prescribed examinations
- •Normal or clinically not significant abnormal values based on investigator judgement on white blood cell count (WBC), C-reactive protein (CRP), Platelets, international normalized ratio (INR), partial thromboplastin time (APTT), haemoglobin (Hgb), Renal and Liver function
- •Females of childbearing potential must have a negative pregnancy test at the Screen Visit
- •Females of childbearing potential must agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which has a proven low failure rate of less than 1%
排除标准
- •More than 20% change in surface area of target ulcer between screening and enrollment visit.
- •There is bone involvement in case of ulcer
- •Patient with a history of bleeding disorder
- •Therapy for anticoagulation
- •Patient receiving corticosteroids, immunosuppressive or cytotoxic agents, and all systemic agents that can affect wound repair
- •Patient with any treatment that might interfere with the assessment of the study treatment
- •Pregnant or likely to become pregnant or lactating women
- •Participation in any type of clinical investigation concurrently or in the last 6 months
- •Positive for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) and syphilis (results within 1 month are acceptable)
- •Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for the participation in the study.
- •Active cancer during chemotherapy or radiotherapy, or recent cancer, if the remission had place less than 5 years before joining the study (except basal cell skin cancer)
- •Patient currently undergoing dialysis for renal insufficiency (serum creatinine ≥2 mg/dL)
- •In the opinion of treating physician, patient not expected to survive beyond 30 days
- •Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance
- •Uncontrolled chronic disease
- •Patient with history of severe alcohol or drug abuse
- •Lack of patient's cooperation
- •Use with blood thinners within 8 weeks of enrollment
- •Systemic treatments with a possible effect on ulcers within 4 weeks prior to enrollment with the following exceptions:
- •Ustekinumab (within 16 weeks prior to enrollment)
- •Adalimumab, infliximab, alefacept (within 8 weeks prior to enrollment)
结局指标
主要结局
Reduction rate of the wound size
时间窗: 28 days
The treatment response will be calculated from wound size before and after treatment.
次要结局
- Improvement Wound pain(28 days)
- Wound closure at Day 28(28 days)
- Improvement of Quality of Life (QoL) - EQ-5D-5L(28 days)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Diabetic Leg UlcersLeg UlcerAutologous Adipose Stromal Vascular FractionMesenchymal Stem CellsAdipose-Derived Mesenchymal Stem CellsDiabetic Foot UlcerNCT05274295Szeged University5
已完成
1 期
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaRelapsed or Refractory Acute Lymphoblastic LeukemiaNCT04230473Juventas Cell Therapy Ltd.10
已完成
1 期
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin LymphomaDiffuse Non-Hodgkin LymphomaNCT04232826Juventas Cell Therapy Ltd.9
进行中（未招募）
1 期
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid TumorsSolid TumorNCT06631079NEC Bio B.V20
已完成
3 期
A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese AdultsPneumonia, Community-AcquiredNCT00360295Pfizer153